Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-001/00
A61M-037/00
C02F-001/44
출원번호
UP-0445965
(2006-06-01)
등록번호
US-7531133
(2009-07-01)
발명자
/ 주소
Hole, Douglas
Miller, Christopher C.
출원인 / 주소
Pulmonox Technologies Corporation
대리인 / 주소
Sidley Austin LLP
인용정보
피인용 횟수 :
22인용 특허 :
111
초록▼
A method of reducing pathogens in blood by exposure to a nitric oxide containing gas in an extracorporeal circuitry is provided. The method includes: obtaining blood from a mammal or a blood source, separating the blood into plasma and blood cells, exposing the plasma to nitric oxide containing gas
A method of reducing pathogens in blood by exposure to a nitric oxide containing gas in an extracorporeal circuitry is provided. The method includes: obtaining blood from a mammal or a blood source, separating the blood into plasma and blood cells, exposing the plasma to nitric oxide containing gas, combining the exposed plasma with the blood cells, reducing nitric oxide content in the recombined blood, and returning the blood to the mammal or blood source.
대표청구항▼
What is claimed is: 1. A method of reducing pathogens in blood, the method comprising: obtaining blood from a mammal or a blood source; separating the blood into plasma and blood cells; exposing the plasma to nitric oxide containing gas; combining the exposed plasma with the blood cells; reducing n
What is claimed is: 1. A method of reducing pathogens in blood, the method comprising: obtaining blood from a mammal or a blood source; separating the blood into plasma and blood cells; exposing the plasma to nitric oxide containing gas; combining the exposed plasma with the blood cells; reducing nitric oxide gas content in the recombined blood by contacting the recombined blood with a gaseous source having a nitric oxide content that is less than the recombined blood; and returning the recombined blood to the mammal or blood source. 2. The method of claim 1, wherein the gaseous source is ambient air. 3. The method of claim 1, further comprising exposing the blood to oxygen, wherein the exposing to oxygen step occurs before the separation step or after the recombining step. 4. The method of claim 1, wherein the separating is through one or more of a filter, a centrifuge, or dialysis. 5. The method of claim 1, wherein the plasma is exposed to a concentration of nitric oxide over a period of time sufficient to reduce pathogen concentration in the blood. 6. The method of claim 1, wherein the pathogens are selected from viruses, bacteria, mycobateria, parasites, and fungi. 7. The method of claim 1, wherein the nitric oxide containing gas is controllably introduced in relation to an amount of plasma separated from the blood. 8. The method of claim 1, wherein the exposing step comprises: providing a semipermeable membrane selectively permeable to nitric oxide gas and impermeable to nitrogen gas adapted to allow contact of an outside of the membrane with the plasma; and delivering nitric oxide containing gas to an inside of the membrane under pressure sufficient to drive the nitric oxide across the membrane for contact with the plasma on the outside of the membrane within a desired concentration range sufficient to reduce pathogen concentration in the plasma. 9. The method of claim 1, wherein the concentration of nitric oxide in the nitric oxide containing gas is about 120 ppm to about 400 ppm. 10. The method of claim 9, wherein the concentration is about 160 ppm to about 220 ppm. 11. The method of claim 1, wherein the concentration of nitric oxide in the nitric oxide containing gas is less than about 120 ppm and more than 0. 12. The method of claim 1, wherein before the combining the exposed plasma with the blood cells step, the exposed plasma is treated by a bacterial particulate filter to reduce levels of lipopolysaccharide (LPS) in the plasma. 13. An extracorporeal blood circuit comprising: an inlet line adapted to obtain blood from a mammal or a blood source; an outlet line adapted to return blood to the mammal or blood source; a fluid circuit for fluid communication between the inlet and the outlet line, wherein the fluid circuit comprises: at least one pump acting on the fluid circuit to circulate the blood therethrough; a separation unit in fluid communication with the inlet line, wherein the separation unit is adapted to separate the blood received from the mammal or source into plasma and blood cells; a nitric oxide unit that exposes the plasma with a nitric oxide containing gas; a mixer for combining the exposed plasma with the blood cells; and a reduction unit for reducing the nitric oxide content in the recombined blood, wherein the reduction unit is in fluid communication with the outlet line and contacts the recombined blood with a gaseous source having a nitric oxide content that is less than the recombined blood. 14. The extracorporeal blood circuit of claim 13, further comprising one or more of a reservoir to collect the blood from the mammal or source, an oxygenator, a dialysis component, an organ perfusion component, a heat exchange component, and an oxygenation component. 15. The extracorporeal blood circuit of claim 13, wherein the gaseous source is ambient air. 16. The extracorporeal blood circuit of claim 13, wherein the separation unit comprises one or more of a filter, a centrifuge, and dialysis. 17. The extracorporeal blood circuit of claim 13, wherein the nitric oxide unit comprises: a semipermeable membrane selectively permeable to nitric oxide gas and impermeable to nitrogen gas adapted to allow contact of an outside of the membrane with the plasma; and nitric oxide containing gas deliverable to an inside of the membrane under pressure sufficient to drive the nitric oxide across the membrane for contact with the plasma on the outside of the membrane within a desired concentration range sufficient to reduce pathogen concentration in the plasma. 18. The extracorporeal blood circuit of claim 13, wherein the concentration of nitric oxide in the nitric oxide containing gas is about 120 ppm to about 400 ppm. 19. The extracorporeal blood circuit of claim 18, wherein the concentration is about 160 ppm to about 220 ppm. 20. The extracorporeal blood circuit of claim 13, wherein the concentration of nitric oxide in the nitric oxide containing gas is less than about 120 ppm and more than 0. 21. The extracorporeal blood circuit of claim 13, further comprising a bacterial particulate filter to reduce levels of lipopolysaccharide (LPS) in the plasma. 22. A method of reducing pathogens in blood, the method comprising: obtaining blood from a mammal or a blood source; separating the blood into plasma and blood cells; exposing the plasma to nitric oxide containing gas; combining the exposed plasma with the blood cells; reducing nitric oxide gas content in the recombined blood by providing a semipermeable membrane selectively permeable to nitric oxide gas in between the recombined blood and a gaseous source; and returning the recombined blood to the mammal or blood source. 23. The method of claim 22, wherein the gaseous source is ambient air. 24. The method of claim 22, further comprising exposing the blood to oxygen, wherein the exposing to oxygen step occurs before the separation step or after the recombining step. 25. The method of claim 22, wherein the separating is through one or more of a filter, a centrifuge, or dialysis. 26. The method of claim 22, wherein the plasma is exposed to a concentration of nitric oxide over a period of time sufficient to reduce pathogen concentration in the blood. 27. The method of claim 22, wherein the pathogens are selected from viruses, bacteria, mycobateria, parasites, and fungi. 28. The method of claim 22, wherein the nitric oxide containing gas is controllably introduced in relation to an amount of plasma separated from the blood. 29. The method of claim 22, wherein the exposing step comprises: providing a semipermeable membrane selectively permeable to nitric oxide gas and impermeable to nitrogen gas adapted to allow contact of an outside of the membrane with the plasma; and delivering nitric oxide containing gas to an inside of the membrane under pressure sufficient to drive the nitric oxide across the membrane for contact with the plasma on the outside of the membrane within a desired concentration range sufficient to reduce pathogen concentration in the plasma. 30. The method of claim 22, wherein the concentration of nitric oxide in the nitric oxide containing gas is about 120 ppm to about 400 ppm. 31. The method of claim 30, wherein the concentration is about 160 ppm to about 220 ppm. 32. The method of claim 22, wherein the concentration of nitric oxide in the nitric oxide containing gas is less than about 120 ppm and more than 0. 33. The method of claim 22, wherein before the combining the exposed plasma with the blood cells step, the exposed plasma is treated by a bacterial particulate filter to reduce levels of lipopolysaccharide (LPS) in the plasma. 34. An extracorporeal blood circuit comprising: an inlet line adapted to obtain blood from a mammal or a blood source; an outlet line adapted to return blood to the mammal or blood source; a fluid circuit for fluid communication between the inlet and the outlet line, wherein the fluid circuit comprises: at least one pump acting on the fluid circuit to circulate the blood therethrough; a separation unit in fluid communication with the inlet line, wherein the separation unit is adapted to separate the blood received from the mammal or source into plasma and blood cells; a nitric oxide unit that exposes the plasma with a nitric oxide gas containing gas; a mixer for combining the exposed plasma with the blood cells; and a reduction unit for reducing the nitric oxide content in the recombined blood, wherein the reduction unit is in fluid communication with the outlet line and comprises a semipermeable membrane selectively permeable to nitric oxide gas operably fitted in between the combined blood and a gaseous source. 35. The extracorporeal blood circuit of claim 34, further comprising one or more of a reservoir to collect the blood from the mammal or source, an oxygenator, a dialysis component, an organ perfusion component, a heat exchange component, and an oxygenation component. 36. The extracorporeal blood circuit of claim 34, wherein the gaseous source is ambient air. 37. The extracorporeal blood circuit of claim 34, wherein the separation unit comprises one or more of a filter, a centrifuge, and dialysis. 38. The extracorporeal blood circuit of claim 34, wherein the nitric oxide unit comprises: a semipermeable membrane selectively permeable to nitric oxide gas and impermeable to nitrogen gas adapted to allow contact of an outside of the membrane with the plasma; and nitric oxide containing gas deliverable to an inside of the membrane under pressure sufficient to drive the nitric oxide across the membrane for contact with the plasma on the outside of the membrane within a desired concentration range sufficient to reduce pathogen concentration in the plasma. 39. The extracorporeal blood circuit of claim 34, wherein the concentration of nitric oxide in the nitric oxide containing gas is about 120 ppm to about 400 ppm. 40. The extracorporeal blood circuit of claim 39, wherein the concentration is about 160 ppm to about 220 ppm. 41. The extracorporeal blood circuit of claim 34, wherein the concentration of nitric oxide in the nitric oxide containing gas is less than about 120 ppm and more than 0. 42. The extracorporeal blood circuit of claim 34, further comprising a bacterial particulate filter to reduce levels of lipopolysaccharide (LPS) in the plasma.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (111)
Bathe Duncan P. L. ; Montgomery Frederick J., Accurate dose nitric oxide pulse delivery device with monitoring and alarms.
Kamibayashi, Masato; Sawamoto, Jiro; Motoyama, Shinji; Endo, Fumiaki, Apparatus for artificial kidney, quality evaluating device for dialyzing fluid and dialyzing means using the same, and fluid circuit.
Ryschka Martin (Stockelsdorf DEX) Falb Wolfgang (Krumesse DEX) Bttner Peter (Stockelsdorf DEX) Wallroth Carl-Friedrich (Lbeck DEX), Arrangement for adding liquid anesthetic to the respiratory gas supplied to a patient.
Saavedra Joseph E. (Thurmont MD) Keefer Larry K. (Bethesda MD) Roller Peter P. (Rockville MD) Akamatsu Miki (Rockville MD), Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of trea.
Saavedra Joseph E. ; Keefer Larry K. ; Roller Peter P. ; Akamatsu Miki, Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same.
Olsson Sven-Gunnar (Arloev SEX) Rydgren Goeran (Bunkeflostrand SEX) Larsson Anders (Kaevlinge SEX) Brauer Stefan (Sodra Sandby SEX) Linge Anders (Kaevlinge SEX), Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject.
Fitzhugh, Anthony L.; Cafferata, Robert; Keefer, Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Keefer Larry K. (Bethesda MD) Hrabie Joseph A. (Frederick MD), Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric o.
Vodovotz, Yoram; Gage, Frederick A., Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use.
Cegielski Michael J. (2404 Temescal Norco CA 91760) van den Berg Teunis T. (24699 Moondshadow Dr. Marino Valley CA 92387), Method and apparatus for selectively mixing gases.
Weinstein, Robert E., Method and device for organizing and coordinating the combined use of liquid medications for continuous nebulization for the treatment of respiratory disorders.
Bathe Duncan P. L. (Madison WI) Kohlmann Thomas S. (McFarland WI) Pinkert John R. (Madison WI) Tham Robert Q. (Middleton WI), Nitric oxide delivery system.
Jeffrey E. Thomas, Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal.
Wink ; Jr. David A. ; Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Hanbauer Ingeborg ; Grisham Matthew B. ; Granger Daniel Neil, Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury.
Joseph E. Saavedra ; Larry K. Keefer ; Peter P. Roller ; Miki Akamatsu, Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same.
Hrabie, Joseph A.; Keefer, Larry K.; Arnold, Ernst V., Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie Joseph A. ; Keefer Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Nitric oxide-releasing compounds to sensitive cancerous cells to chemotherapeutic agents.
Arnold, Ernst V.; Keefer, Larry K.; Hrabie, Joseph A., Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same.
Fitzhugh Anthony L. ; Cheng Peiwen ; Saavedra Joseph ; Cafferata Robert ; Hendriks Marc,NLX ; Keefer Larry K. ; Tedeschi Eugene ; Verhoeven Michel L. P. M.,NLX, Nitric oxide-releasing metallic medical devices.
Fitzhugh, Anthony L.; Cheng, Peiwen; Saavedra, Joseph; Cafferata, Robert; Hendriks, Marc; Keefer, Larry K.; Tedeschi, Eugene; Verhoeven, Michel I. P. M., Nitric oxide-releasing metallic medical devices.
Kim,Hyung Min; You,HyungJa; Seo,Sang Bong, Pharmaceutical composition for increasing the production of nitric oxide and IFN-γ, and process for preparation thereof.
Sheu Lien-Lung (Scotch Plains NJ) Ramachandran Ramakrishnan (Allendale NJ) Galica Theodore R. (Glen Gardner NJ), Process for the purification of nitric oxide.
Frostell Claes G. (Vallingby SEX) Hedenstierna Goran (Djursholm SEX) Hogman Marieann E. (Alunda MA SEX) Loscalzo Joseph (Dedham MA) Stamler Jonathan S. (Boston MA), Systemic effects of nitric oxide inhalation.
Mitchell James B. (Damascus MD) Russo Angelo (Bethesda MD) Krishna Murali C. (Derwood MD) Wink ; Jr. David A. (Hagerstown MD) Liebmann James E. (Albuquerque NM), Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents.
Korthuis Ronald J. (Shreveport LA) Kong Lipu (Shreveport LA) Keefer Larry K. (Bethesda MD), Use of nitric oxide-releasing agents for reducing metastasis risk.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers.
Jonathan S. Stamler ; Claude A. Piantadosi ; Mark W. Dewhirst, Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Greenberg, David G.; Puritz, Scott; Koutchma, Tatiana; Walterspiel, Juan N., Modular extracorporeal systems and methods for treating blood-borne diseases.
Greenberg, David G.; Puritz, Scott; Koutchma, Tatiana; Walterspiel, Juan N., Modular extracorporeal systems and methods for treating blood-borne diseases.
Ferren, Bran; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Treatment indications informed by a priori implant information.
Ferren, Bran; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Treatment indications informed by a priori implant information.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.